Vitina Carriero, Francesca Bertolini, Elisa Arrigo, Giuseppe Guida, Stefano Levra, Mirella Profita, Isabella Gnemmi, Antonino Di Stefano, Fabio Luigi Massimo Ricciardolo
{"title":"轻至重度哮喘合并慢性鼻窦炎患者T2/T3内型重叠的证据:一项初步研究","authors":"Vitina Carriero, Francesca Bertolini, Elisa Arrigo, Giuseppe Guida, Stefano Levra, Mirella Profita, Isabella Gnemmi, Antonino Di Stefano, Fabio Luigi Massimo Ricciardolo","doi":"10.1513/AnnalsATS.202410-1076OC","DOIUrl":null,"url":null,"abstract":"<p><strong>Rationale: </strong>Asthma and chronic rhinosinusitis (CRS) often co-occur and share heterogenous inflammatory processes resulting in frequent exacerbations and poor clinical control.</p><p><strong>Objectives: </strong>This observational cross-sectional study aims to characterize asthma with comorbid CRS and to understand whether CRS could influence asthma severity focusing on the bronchial immune-inflammatory and remodelling response.</p><p><strong>Methods: </strong>We assessed the number of inflammatory cells and the expression of T2/T3 and remodelling biomarkers in the bronchial mucosa of 47 mild-to-severe asthmatics' bronchial biopsies by immunohistochemistry/immunofluorescence. We compared the clinical, functional and biological data of asthmatics without (As) or with CRS (As+CRS) (As/As+CRS: N=16/31) in the presence/absence of nasal polyps (As+CRSwNP/As+CRSsNP: N=15/16) and further stratified in mild and severe asthma without CRS (MAs/SAs: N=11/5) vs mild/severe asthma with CRS (MAs+CRS/SAs+CRS: N=15/16). Measurements and main results As+CRS patients had later asthma onset and higher blood eosinophils and FENO than As (p<0.01). As+CRSwNP had a higher exacerbation rate than As (p<0.01) and higher blood eosinophilia than both As+CRSsNP and As (p<0.01). As+CRSsNP showed higher RV(%predicted) and lower FEV1/FVC than As. Immunohistochemistry and immunofluorescence showed that As+CRS, compared to As (p<0.05), had higher and concomitant expression of T2/T3 inflammatory biomarkers and remodelling evidence (number of eosinophils, CD4+, eotaxin-3+, IL-5+, IL-9+, IL-17A+, IL-22+ cells and sub-epithelial basal membrane thickness) in the bronchial lamina propria as well as higher percentage of GATA3+ cells and a greater tendency of RORγT+ cells (p>0.05). Higher expression of T2/T3 cytokines - IL-13+, eotaxin-3+, IL-9+, TSLP+, IL-17A+ and IL-17F+ cells - was observed in SAs+CRS. Two-way ANOVA showed that both comorbid CRS and asthma severity modulate IL-13 and IL-17A bronchial expression in asthma. Conclusions Our results confirm a higher proportion of T2 clinical phenotype (FENO and blood eosinophils) in asthma with comorbid CRS, but revealed a more complex bronchial immune-inflammatory response suggesting an overlapping interplay of T2/T3 processes as underlying mechanisms related to this clinical asthma phenotype.</p>","PeriodicalId":93876,"journal":{"name":"Annals of the American Thoracic Society","volume":" ","pages":""},"PeriodicalIF":5.4000,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Evidence of T2/T3 Endotype Overlap in Mild-to-Severe Asthma with Chronic Rhinosinusitis: A Pilot Study.\",\"authors\":\"Vitina Carriero, Francesca Bertolini, Elisa Arrigo, Giuseppe Guida, Stefano Levra, Mirella Profita, Isabella Gnemmi, Antonino Di Stefano, Fabio Luigi Massimo Ricciardolo\",\"doi\":\"10.1513/AnnalsATS.202410-1076OC\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Rationale: </strong>Asthma and chronic rhinosinusitis (CRS) often co-occur and share heterogenous inflammatory processes resulting in frequent exacerbations and poor clinical control.</p><p><strong>Objectives: </strong>This observational cross-sectional study aims to characterize asthma with comorbid CRS and to understand whether CRS could influence asthma severity focusing on the bronchial immune-inflammatory and remodelling response.</p><p><strong>Methods: </strong>We assessed the number of inflammatory cells and the expression of T2/T3 and remodelling biomarkers in the bronchial mucosa of 47 mild-to-severe asthmatics' bronchial biopsies by immunohistochemistry/immunofluorescence. We compared the clinical, functional and biological data of asthmatics without (As) or with CRS (As+CRS) (As/As+CRS: N=16/31) in the presence/absence of nasal polyps (As+CRSwNP/As+CRSsNP: N=15/16) and further stratified in mild and severe asthma without CRS (MAs/SAs: N=11/5) vs mild/severe asthma with CRS (MAs+CRS/SAs+CRS: N=15/16). Measurements and main results As+CRS patients had later asthma onset and higher blood eosinophils and FENO than As (p<0.01). As+CRSwNP had a higher exacerbation rate than As (p<0.01) and higher blood eosinophilia than both As+CRSsNP and As (p<0.01). As+CRSsNP showed higher RV(%predicted) and lower FEV1/FVC than As. Immunohistochemistry and immunofluorescence showed that As+CRS, compared to As (p<0.05), had higher and concomitant expression of T2/T3 inflammatory biomarkers and remodelling evidence (number of eosinophils, CD4+, eotaxin-3+, IL-5+, IL-9+, IL-17A+, IL-22+ cells and sub-epithelial basal membrane thickness) in the bronchial lamina propria as well as higher percentage of GATA3+ cells and a greater tendency of RORγT+ cells (p>0.05). Higher expression of T2/T3 cytokines - IL-13+, eotaxin-3+, IL-9+, TSLP+, IL-17A+ and IL-17F+ cells - was observed in SAs+CRS. Two-way ANOVA showed that both comorbid CRS and asthma severity modulate IL-13 and IL-17A bronchial expression in asthma. Conclusions Our results confirm a higher proportion of T2 clinical phenotype (FENO and blood eosinophils) in asthma with comorbid CRS, but revealed a more complex bronchial immune-inflammatory response suggesting an overlapping interplay of T2/T3 processes as underlying mechanisms related to this clinical asthma phenotype.</p>\",\"PeriodicalId\":93876,\"journal\":{\"name\":\"Annals of the American Thoracic Society\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":5.4000,\"publicationDate\":\"2025-09-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of the American Thoracic Society\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1513/AnnalsATS.202410-1076OC\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of the American Thoracic Society","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1513/AnnalsATS.202410-1076OC","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Evidence of T2/T3 Endotype Overlap in Mild-to-Severe Asthma with Chronic Rhinosinusitis: A Pilot Study.
Rationale: Asthma and chronic rhinosinusitis (CRS) often co-occur and share heterogenous inflammatory processes resulting in frequent exacerbations and poor clinical control.
Objectives: This observational cross-sectional study aims to characterize asthma with comorbid CRS and to understand whether CRS could influence asthma severity focusing on the bronchial immune-inflammatory and remodelling response.
Methods: We assessed the number of inflammatory cells and the expression of T2/T3 and remodelling biomarkers in the bronchial mucosa of 47 mild-to-severe asthmatics' bronchial biopsies by immunohistochemistry/immunofluorescence. We compared the clinical, functional and biological data of asthmatics without (As) or with CRS (As+CRS) (As/As+CRS: N=16/31) in the presence/absence of nasal polyps (As+CRSwNP/As+CRSsNP: N=15/16) and further stratified in mild and severe asthma without CRS (MAs/SAs: N=11/5) vs mild/severe asthma with CRS (MAs+CRS/SAs+CRS: N=15/16). Measurements and main results As+CRS patients had later asthma onset and higher blood eosinophils and FENO than As (p<0.01). As+CRSwNP had a higher exacerbation rate than As (p<0.01) and higher blood eosinophilia than both As+CRSsNP and As (p<0.01). As+CRSsNP showed higher RV(%predicted) and lower FEV1/FVC than As. Immunohistochemistry and immunofluorescence showed that As+CRS, compared to As (p<0.05), had higher and concomitant expression of T2/T3 inflammatory biomarkers and remodelling evidence (number of eosinophils, CD4+, eotaxin-3+, IL-5+, IL-9+, IL-17A+, IL-22+ cells and sub-epithelial basal membrane thickness) in the bronchial lamina propria as well as higher percentage of GATA3+ cells and a greater tendency of RORγT+ cells (p>0.05). Higher expression of T2/T3 cytokines - IL-13+, eotaxin-3+, IL-9+, TSLP+, IL-17A+ and IL-17F+ cells - was observed in SAs+CRS. Two-way ANOVA showed that both comorbid CRS and asthma severity modulate IL-13 and IL-17A bronchial expression in asthma. Conclusions Our results confirm a higher proportion of T2 clinical phenotype (FENO and blood eosinophils) in asthma with comorbid CRS, but revealed a more complex bronchial immune-inflammatory response suggesting an overlapping interplay of T2/T3 processes as underlying mechanisms related to this clinical asthma phenotype.